AIFFTechnology · Software - ApplicationTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Firefly Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AIFF, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIFF appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 15% of US stocks
Cheaper than 69% of US stocks
Cheaper than 66% of US stocks
Higher than 91% of US stocks
Higher than 98% of US stocks
Higher than 57% of US stocks
Higher than 8% of US stocks
Higher than 97% of US stocks
Higher than 17% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Firefly Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Firefly Neuroscience announced a 291% year-over-year increase in TMS center customer brain scan volumes, using its FDA-cleared, AI-powered EEG/ERP platform Evoke™.
Why it matters — The significant volume growth signals rising adoption of Firefly's platform among TMS centers, which could strengthen the company's commercial traction.
Firefly Neuroscience (AIFF) and Next Health launched a Precision Cognitive Health Initiative. Separately, an FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax.
Why it matters — For AIFF watchers, the launch of the cognitive health initiative could expand the company's commercial reach, while the FDA committee's recommendation may open broader access to neuroprotective peptides relevant to AIFF's focus.
As at 22 Aug 2026, Firefly Neuroscience, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
No analyst covering Firefly Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIFF are extrapolating price history, which says nothing about the business.
Firefly Neuroscience, Inc. returned -57.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Firefly Neuroscience Inc. is a medical technology and artificial intelligence company that develops neuroscientific software solutions to improve brain health outcomes for patients with neurological and mental disorders.
The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes". Firefly Neuroscience announced a 291% year-over-year increase in TMS center customer brain scan volumes, using its FDA-cleared, AI-powered EEG/ERP platform Evoke™.
Firefly Neuroscience Inc. is a medical technology and artificial intelligence company that develops neuroscientific software solutions to improve brain health outcomes for patients with neurological and mental disorders. Its flagship offering, the FDA-510(k) cleared Brain Network Analytics (BNA™) platform, uses AI and machine learning to analyze standardized electroencephalogram (EEG) and event-related potential (ERP) data from rest and cognitive tasks. This technology compares individual brain activity patterns to a proprietary normative database, providing objective measures of functional brain networks and cognitive performance to support diagnosis and treatment monitoring for conditions including depression, dementia, anxiety disorders, concussions, and ADHD. Firefly Neuroscience Inc. also provides the CLEAR Platform, a preprocessing tool that enhances EEG data quality by removing artifacts using advanced signal processing and NVIDIA GPU acceleration. The company serves pharmaceutical and medtech firms for drug research and clinical trials, as well as medical practitioners and clinics. It maintains collaborations with academic institutions and partners in neuroscience research. Founded in 2006 and headquartered in Kenmore, New York, Firefly Neuroscience Inc. operates primarily in North America with a focus on its BNA platform segment.
CEO Mr. Greg Lipschitz · 17 employees · United States · https://fireflyneuro.com